Beta-Blockers: Current State of Knowledge and Perspectives

Mini Rev Med Chem. 2016;16(1):40-54. doi: 10.2174/1389557515666151016125948.

Abstract

It has been over half a century since propranolol, the first beta-blocker, was developed for medical treatment. Since that time a large number of compounds from this group have been synthesised and many are now in clinical use. The structure, function, pharmacokinetics, and mechanism of beta-blockers have been established. The possibilities for their use in treating different conditions continue to evolve. Since the discovery of later generation beta-blockers, such as carvedilol and nebivolol, the search for new compounds continues, and may include known substances with beta-blocking properties which could extend their therapeutic potential.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists* / chemistry
  • Adrenergic beta-Antagonists* / pharmacology
  • Adrenergic beta-Antagonists* / therapeutic use
  • Chemistry, Pharmaceutical / trends*
  • Glaucoma / drug therapy
  • Humans
  • Hypertension / drug therapy
  • Hyperthyroidism / drug therapy
  • Migraine Disorders / drug therapy
  • Molecular Structure

Substances

  • Adrenergic beta-Antagonists